Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly …
MW Deininger, KJ Kopecky, JP Radich… - British journal of …, 2014 - Wiley Online Library
The standard dose of imatinib for newly diagnosed patients with chronic phase chronic
myeloid leukaemia (CP‐CML) is 400 mg daily (IM400), but the optimal dose is unknown …
myeloid leukaemia (CP‐CML) is 400 mg daily (IM400), but the optimal dose is unknown …
Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience
RM Braziel, TM Launder, BJ Druker… - Blood, The Journal …, 2002 - ashpublications.org
Imatinib mesylate, an Abl kinase inhibitor, produces sustained complete hematologic
responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and …
responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and …
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy
A Abe, Y Minami, F Hayakawa, K Kitamura… - International journal of …, 2008 - Springer
Chronic myelogenous leukemia (CML) is effectively treated with imatinib mesylate (IM), a
small molecule inhibitor of the BCR-ABL tyrosine kinase that is expressed in the entire …
small molecule inhibitor of the BCR-ABL tyrosine kinase that is expressed in the entire …
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec) Bone marrow histopathology and correlation with genetic status
JL Frater, MS Tallman, D Variakojis… - American journal of …, 2003 - academic.oup.com
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic
status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia …
status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia …
Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
HX Lin, J Sjaarda, J Dyck, R Stringer… - European journal of …, 2016 - Wiley Online Library
Objectives Achieving a major molecular response (MMR) is the goal of imatinib therapy for
chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript …
chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript …
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate …
S Chu, H Xu, NP Shah, DS Snyder, SJ Forman… - Blood, 2005 - ashpublications.org
The BCR-ABL kinase inhibitor imatinib mesylate induces complete cytogenetic response
(CCR) in a high proportion of chronic myelogenous leukemia (CML) patients. However …
(CCR) in a high proportion of chronic myelogenous leukemia (CML) patients. However …
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia …
H Kantarjian, M Talpaz, S O'Brien… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of< 35%) or a complete
cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival …
cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …
P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - nature.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …